West Pharmaceutical
218 hedge funds and large institutions have $3.92B invested in West Pharmaceutical in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 77 increasing their positions, 87 reducing their positions, and 12 closing their positions.
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
2% more funds holding
Funds holding: 213 → 218 (+5)
0.4% more ownership
Funds ownership: 93.62% → 94.01% (+0.4%)
0% more call options, than puts
Call options by funds: $209K | Put options by funds: $209K
3% less capital invested
Capital invested by funds: $4.05B → $3.92B (-$124M)
11% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 87
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$76.9M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$7.81M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.38M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.2M |
| 5 |
Comerica Bank
Dallas,
Texas
|
+$5.34M |
Top Sellers
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
-$22.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$22.2M |
| 3 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$14.9M |
| 4 |
Neuberger Berman Group
New York
|
-$10.6M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$6.95M |
WST Hedge Fund Activity: Q2 2015 in Review
218 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2015, worth a combined $3.92B — down 3.1% from $4.05B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new WST positions and 12 closed out — a net gain of 5 holders — while 77 added to existing stakes and 87 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $76.9M. The largest seller was RS Investment Management, cutting an estimated $22.5M.
- 218 institutional investors held West Pharmaceutical (WST) as of Q2 2015, up from 213 in Q1 2015.
- Funds reported $3.92B of West Pharmaceutical stock for Q2 2015, down 3.1% quarter-over-quarter.
- 17 funds opened new West Pharmaceutical positions in Q2 2015 and 12 closed out, a net change of +5 holders.
- The largest West Pharmaceutical buyer in Q2 2015 was T. Rowe Price Associates, an estimated $76.9M added.
- The largest West Pharmaceutical seller in Q2 2015 was RS Investment Management, an estimated $22.5M sold.
Based on aggregated 13F filings for Q2 2015.